VanEck Associates’s Redhill Biopharma RDHL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-8
| Closed | -$59K | – | 1306 |
|
|
2021
Q1 | $59K | Hold |
8
| – | – | ﹤0.01% | 1065 |
|
|
2020
Q4 | $65K | Hold |
8
| – | – | ﹤0.01% | 948 |
|
|
2020
Q3 | $84K | Hold |
8
| – | – | ﹤0.01% | 902 |
|
|
2020
Q2 | $54K | Sell |
8
-3
| -27% | -$20.3K | ﹤0.01% | 903 |
|
|
2020
Q1 | $50K | Hold |
11
| – | – | ﹤0.01% | 871 |
|
|
2019
Q4 | $65K | Buy |
11
+2
| +22% | +$11.8K | ﹤0.01% | 870 |
|
|
2019
Q3 | $67K | Hold |
9
| – | – | ﹤0.01% | 780 |
|
|
2019
Q2 | $61K | Sell |
9
-2
| -18% | -$13.6K | ﹤0.01% | 772 |
|
|
2019
Q1 | $92K | Hold |
11
| – | – | ﹤0.01% | 749 |
|
|
2018
Q4 | $60K | Buy |
11
+3
| +38% | +$16.4K | ﹤0.01% | 753 |
|
|
2018
Q3 | $67K | Buy |
8
+1
| +14% | +$8.38K | ﹤0.01% | 748 |
|
|
2018
Q2 | $61K | Buy |
7
+3
| +75% | +$26.1K | ﹤0.01% | 767 |
|
|
2018
Q1 | $22K | Hold |
4
| – | – | ﹤0.01% | 716 |
|
|
2017
Q4 | $20K | Sell |
4
-2
| -33% | -$10K | ﹤0.01% | 713 |
|
|
2017
Q3 | $60K | Buy |
6
+1
| +20% | +$10K | ﹤0.01% | 709 |
|
|
2017
Q2 | $45K | Sell |
5
-25
| -83% | -$225K | ﹤0.01% | 725 |
|
|
2017
Q1 | $284K | Hold |
30
| – | – | ﹤0.01% | 655 |
|
|
2016
Q4 | $310K | Buy |
30
+20
| +200% | +$207K | ﹤0.01% | 630 |
|
|
2016
Q3 | $134K | Hold |
10
| – | – | ﹤0.01% | 694 |
|
|
2016
Q2 | $105K | Buy |
10
+1
| +11% | +$10.5K | ﹤0.01% | 683 |
|
|
2016
Q1 | $116K | Hold |
9
| – | – | ﹤0.01% | 662 |
|
|
2015
Q4 | $121K | Buy |
9
+1
| +13% | +$13.4K | ﹤0.01% | 603 |
|
|
2015
Q3 | $109K | Buy |
8
+1
| +14% | +$13.6K | ﹤0.01% | 617 |
|
|
2015
Q2 | $130K | Buy |
+7
| New | +$130K | ﹤0.01% | 629 |
|